Literature DB >> 17433431

The role of the immune system in preeclampsia.

Shigeru Saito1, Arihiro Shiozaki, Akitoshi Nakashima, Masatoshi Sakai, Yasushi Sasaki.   

Abstract

Recent data demonstrate that an altered immune response may play a key role in the development of preeclampsia. Some epidemiological findings and animal models support this idea. In this article, we review the innate immune system and adaptive immune system in preeclampsia and discuss the pathophysiology of preeclampsia from an immunological viewpoint. The most characteristic immunological finding in preeclampsia is the activation of both the innate and adaptive immune system. Activated neutrophils, monocytes, and NK cells initiate inflammation which induce endothelial dysfunction, and activated T cells may support inadequate tolerance during pregnancy. The cytokine profile in preeclampsia shows that the production of type 1 cytokines, which induce inflammation, is dominant while the production of type 2 cytokines, which regulates inflammation, is suppressed. Furthermore, the immunoregulatory system is down-regulated in preeclampsia and persistent inflammation reduces regulatory T cell function. Therefore, systematical immunoactivation may be one cause of preeclampsia.

Entities:  

Mesh:

Year:  2007        PMID: 17433431     DOI: 10.1016/j.mam.2007.02.006

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  95 in total

1.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

2.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

Review 3.  Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Sajjadh M J Ali; Raouf A Khalil
Journal:  Expert Opin Ther Targets       Date:  2015-08-17       Impact factor: 6.902

4.  Interleukin-17 signaling mediates cytolytic natural killer cell activation in response to placental ischemia.

Authors:  Olivia K Travis; Dakota White; Cedar Baik; Chelsea Giachelli; Willie Thompson; Cassandra Stubbs; Mallory Greer; James P Lemon; Jan Michael Williams; Denise C Cornelius
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-22       Impact factor: 3.619

5.  Effect of lipoxin A₄ on IL-1β production of monocytes and its possible mechanism in severe preeclampsia.

Authors:  Jianfang Wang; Yinping Huang; Yanjun Huang; Jie Zhou; Xiaoli Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

6.  Placental microRNA expression in pregnancies complicated by preeclampsia.

Authors:  Daniel A Enquobahrie; Dejene F Abetew; Tanya K Sorensen; David Willoughby; Kumaravel Chidambaram; Michelle A Williams
Journal:  Am J Obstet Gynecol       Date:  2010-11-20       Impact factor: 8.661

7.  Maternal tryptophan and kynurenine pathway metabolites and risk of preeclampsia.

Authors:  Roy M Nilsen; Anne-Lise Bjørke-Monsen; Oivind Midttun; Ottar Nygård; Eva R Pedersen; Arve Ulvik; Per Magnus; Håkon K Gjessing; Stein Emil Vollset; Per Magne Ueland
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

8.  Mid-pregnancy circulating cytokine levels, histologic chorioamnionitis and spontaneous preterm birth.

Authors:  Julia Warner Gargano; Claudia Holzman; Patricia Senagore; Poul Thorsen; Kristin Skogstrand; David M Hougaard; Mohammad H Rahbar; Hwan Chung
Journal:  J Reprod Immunol       Date:  2008-09-23       Impact factor: 4.054

9.  Decreased expression and DNA methylation levels of GATAD1 in preeclamptic placentas.

Authors:  Xiaoling Ma; Jinping Li; Brian Brost; Wenjun Cheng; Shi-Wen Jiang
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

10.  IL-17 producing innate lymphoid cells 3 (ILC3) but not Th17 cells might be the potential danger factor for preeclampsia and other pregnancy associated diseases.

Authors:  Prince A Barnie; Xin Lin; Yueqin Liu; Huaxi Xu; Zhaoliang Su
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.